Podcasts: By The Chromodiversity Foundation

Photo by: Harry Cunningham

We think you will like this excellent podcast initiative by Elliot Polak, of My XXY – Chromodiversity Foundation that makes understanding research papers a great deal easier for those who yearn for information but fail to grasp the medical language they use. Elliot breaks it down into its raw form and goes to great lengths to ensure it is understood.

Invisible Gender in Medical Research

The thing about being XXY and/or variant is how we are continually compared with XY Males even though we are biologically different and respond differently in major health disparities  such as (in this instance) Cardiovascular health and disease. Not helpful to the XXY is a pathological relience on the Y chromosome determining maleness and how clinicians who work in that area seem stuck in a time capsule, afraid to relinquish the last fragile thread of what makes men males. It’s that same stubburness and an insistance by parent lobby groups to have their children placed on exogenous testosterone in infancy, that the goal post for Klinefelter’s Syndrome (a disease of the testis that sometimes happens at puberty) has been drasticly scaled back to now include a “mini puberty” evident in the first few weeks of life. The fact that XXY’s experience this “mini puberty” naturally does not seem to matter one ioata where doctors are only too eager to please a parent, the Health Authorities are notified the child has a micro phallus and Klinefelter’s Syndrome, even though neither of those are true.

Four decades ago, gender disparities research was uncommon. A quick search of PubMed today reveals how far we have come, yielding 8391 published articles with either the term gender disparities or gender differences in the title. A similar search for disparities in transgender or gender minority populations, however, yielded only 67 articles with only a handful focused on conditions outside of mental and sexual health. This discordance exists because, until recently, our society has posited gender as binary—male or female—and we have viewed individuals and conducted our research with this paradigm.

The past 2 decades have ushered in a new and more nuanced societal understanding of gender—one where gender is a spectrum that includes traditional cisgender male and female identities (ie, those whose gender identity matches their biological sex) but also individuals who identify themselves as transgender, gender non-conforming/nonbinary (neither exclusively of male or female gender identity), intersex (with dual male and female sex phenotypes, indeterminate sex phenotype, or with mosaic genetics), agender (no gender identity), or one of many other non-cisgender classifications. The number of transgender individuals in the United States is currently estimated to be 1.4 million, with varying prevalence of 0.3% to 0.8% across the 50 states.

Alarmingly, recent research has found that a transgender (ie, any non-cisgender) individual is more likely to be poor, unemployed, or homeless. Rates of attempted suicide are much more common in transgender individuals (40% versus 5%) as are rates of stress, depression, and intimate partner violence. Moreover, many transgender individuals avoid seeking medical care because of lack of health insurance or prior negative health encounters where they were not recognized as full human beings (eg, intentionally not being addressed by their preferred name or gender pronouns, questioned for their gender identity choices, mocked for the effects of hormonal therapies on their bodies). In fact, 19% of transgender people have been refused treatment solely on the basis of their gender identity, and 23% have avoided care because of fear of discrimination against them. Transgender people are also reluctant to reveal their bodies, especially if they have not fully transitioned with hormone or surgical treatments.

Against this backdrop, in this issue of Circulation: Cardiovascular Quality and Outcomes, Alzahrani et al have leveraged the Behavioral Risk Factor Surveillance System data from the Centers for Disease Control and Prevention to compare the prevalence of myocardial infarction between transgender versus cisgender individuals. The Behavioral Risk Factor Surveillance System is a unique national dataset as it can be used to assess gender as a multilevel category, thereby avoiding assumptions of gender as only a binary choice of male versus female. The investigators found that transgender males and females have higher rates of prior myocardial infarction than cisgender individuals (except when comparing transgender women versus cisgender men) but that this relationship was particularly striking (≈5-fold higher odds) when comparing transgender men versus cisgender women. These results were consistent after adjustment for a limited number of cardiovascular and lifestyle risk factors.

This article was notable in several respects. First, it reported on the health of transgender individuals as a separate gender group, and the focus was not on mental or sexual health. This article remains one of only a handful of cardiovascular publications where gender was assessed at multiple levels and not assumed to be binary. Second, the authors leveraged a national dataset that collected information on gender identity through telephone interviews, which may be viewed as less threatening than in-person interviews where transgender identity may not be as willingly volunteered.

And third, the authors found an important association for myocardial infarction risk among transgender individuals, especially among transgender men as compared with cisgender women.

This report provides important insights, given conflicting reports from 2 recent studies, in which one similarly found a higher risk for myocardial infarction among transgender men versus cisgender men and women and for transgender women versus cisgender women but not for transgender women versus cisgender men, and the other found no increased risk for myocardial infarction among transgender individuals (although transgender women in this study had higher rates of venous thromboembolism as compared with cisgender men).

No doubt, there are limitations with the methods and findings from this article. First, the nature of the Behavioral Risk Factor Surveillance System data makes this a cross-sectional study. As such, the association between transgender status and a higher risk of myocardial infarction is hypothesis-generating at best, and causation cannot be inferred, especially because the authors were not able to establish whether the myocardial infarction occurred before the individual’s recognition of their transgender identity.

Second, the authors had little information as to the reasons for higher risk of myocardial infarction among transgender individuals. The Behavioural Risk Factor Surveillance System data do not collect data on use and duration of use of gender-affirming hormone therapy or the duration of time one has identified themselves as transgender. Although there are potential risks of myocardial infarction with both testosterone and estrogen hormone therapies in other contexts, the risks of testosterone in transgender men and estrogen in transgender women are not well understood. Because prior research has also found that a transgender person has a higher likelihood of suicide, depression, stress, unemployment lack of insurance, and poverty, which are all well-known determinants of cardiovascular health, it is unclear whether transgender individuals in this study may have had higher risks for myocardial infarction because of these social determinants of health.

Had the authors possessed information on the duration of hormone-affirming therapy, psychosocial and economic variables, and duration of transgender status, they may have been able to provide greater insights into potential mechanisms by which transgender status increases risks for myocardial infarction. Long-term cohort studies with granular information on transgender status and treatments are critically needed, with an emphasis of not only delineating cardiovascular issues but also non-cardiovascular risks and benefits

And third, the authors categorised individuals who were non-binary (ie, gender nonconforming) using an invalidated formula.It was unclear what proportion of transgender men and women were actually non-binary. Non binary identity refers to individuals who see themselves as neither exclusively of male or female gender identity or as a combination of both; therefore, non binary individuals may not take gender-affirming hormones (testosterone or estrogen) and may instead choose hormone blockers (such as vantas or lupron for biological females to block the effects of estrogen). The risks for transgender individuals who take gender affirming hormones versus hormone blockers may differ if the majority of this risk is mediated by hormones rather than higher rates of stress, depression, and poverty found in the transgender population.

Nonetheless, Alzahrani et al have continued an important dialogue on transgender health research. It is time that transgender individuals are not treated as second-class citizens. As researchers, we can start by doing something easy but transformative we should avoid imposing the false dichotomy of asking patients to identify themselves as either male or female.

Instead, we should provide, at a minimum, 5 gender categories for all patients: cisgender male, transgender male, cisgender female, transgender female, and other (eg, non-binary). We should actively use the term cisgender for those who do not view themselves as transgender.

Doing so will normalise transgender identity and avoid putting the burden of differentness on transgender peoples as if they are a deviation from the norm. And defining gender as more than a binary choice will allow us to gain deeper insights into whether transgender and non-binary individuals have higher risks for certain outcomes regardless of whether gender is the independent variable of interest. Being intentional about classifying gender as multiple categories will passively generate volumes of research data for cisgender, transgender, and non-binary individuals and rapidly advance our understanding of outcome differences for different gender groups.

Transgender people are a vulnerable population that are hidden from the majority of researchers unless one knows someone personally to understand their stigma, ostracism, stresses, and fears. In 1952, Invisible Man by Ralph Ellison provided a complex portrayal of black identity and individuality. In the prologue, Ellison wrote, “I am invisible, understand, simply because people refuse to see me.” Today, the contemporary invisible individual is the transgender person. As researchers, we can take the first step and recognise those who are invisible by acknowledging that gender is more than binary and conduct our research accordingly.

This article was originally posted by the American Heart Associations journal, Circulation: Cardiovascular Quality and Outcomes 

Hyperestrogenism The Elephant in Klinefelter’s Syndrome

Photo Credit: William Daigneault

What is clear is that a condition of relative hyperestrogenism is present in these patients, since the estradiol/testosterone ratio is altered thanks to the lower concentrations of total serum testosterone in presence of normal serum estradiol. Accordingly, the results of this study confirm unequivocally the significant reduction in total serum testosterone in men with KS compared to controls which seems to be also responsible for the significant, higher estradiol/testosterone ratio in men with KS compared to control subjects.

Relative Hyperestrogenism in Klinefelter Syndrome


With this in view, the most important result of this study is the finding of a significant increase of the estradiol/testosterone ratio in men with KS compared to control
subjects, suggesting a clinical condition of testosterone deficiency coupled with relative estrogen excess. Currently, only a few studies provided direct evidence on the unbalanced estradiol/testosterone ratio in men with KS. This imbalance in circulating sex steroids is a peculiar characteristic of men with KS in whom serum estradiol is in the highest quartile of the normal range notwithstanding low circulating levels of its precursor testosterone.

Probably, the activity and expression of the aromatase enzyme is increased in these patients, but information about the underlying mechanism is still not available in the literature. It is known that elevated serum LH levels may increase aromatase activity leading to a relative increase of estradiol secretion from the testes, but to what extent this mechanism operates in men with KS is not known. There is only indirect evidence by in vitro study.

Continue reading…….

Inside the Experiment That Could End Infertility

IVG uses stem cells — the biological clay that can form every body part — to build sex cells, which in humans are sperm and eggs. If successful, the technique could solve infertility due to age, cancer, or various disorders, which today affects tens of millions of people. It could also stretch the possibilities for genetic kinship and nudge biology to match the ever-evolving concept of a nuclear family. Same-sex partners could both be genetically related to their children — a woman could make sperm, a man an egg. People who are transgender could make sex cells that match their identity, rather than their biology. A single woman could have a child with herself. The science is still in early stages, but so far the basic concept has worked, more or less, in live mice and in human cells in a petri dish. A handful of labs across the world hope it’ll also work in people.
Read the full article at Medium.com